

Supplemental Figures




Figure S1. Serum phytocannabinoid profile in adolescent IBD cannabis users.

Serum phytocannabinoid levels of adolescent IBD patients enrolled in the CANDID clinical trial who self-identified as having ever used cannabis. Levels are organized by number of patient positive tests starting at cannabichromine (CBC; n = 3) and increasing to THC-COOH (n = 20). Serum levels of cannabinol (detectable range 1.56 to 400 ng/mL), cannabigerol (0.78 to 400 ng/mL), tetrahydrocannabivarin (0.78 to 400 ng/mL) and cannabidivarin (0.78 to 400 ng/mL) not shown here, were all below the limit of detection in all cases. Results represent the mean \pm SEM for n= 3-20 patients.




Figure S2. Production of cytokines unchanged in stimulated PBMCs from pediatric IBD patients using cannabis compared to non-users.

(A) There was no difference in Th1 (IL-12), Th2 (IL-4), (B) Th17 (IL-17) or Treg (IL-10) associated cytokines between IBD patients who had detectable blood cannabis metabolite levels (“users”) and non-users after 24h restimulation with anti-CD3/CD28 antibodies.

Results represent mean \pm SEM for N \geq 12.